Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	20	27.9	71.6	(43.7-110.5)
Female	11	10.3	106.3	(53.0-190.3)
Brain and Other Nervous System				
Male	2	5.3	nc	(nc-nc)
Female	7	4.4	157.6	(63.1-324.7)
Breast				
Male	1	1.0	nc	(nc-nc)
Female	136	112.9	120.5	(101.1-142.5)
Cervix Uteri				
Female	1	3.7	nc	(nc-nc)
Colon / Rectum				
Male	36	30.8	116.8	(81.8-161.7)
Female	32	30.5	104.9	(71.7-148.1)
Esophagus				
Male	4	7.3	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)
Hodgkin Lymphoma				
Male	3	2.0	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	17	15.9	106.6	(62.1-170.7)
Female	7	9.0	78.2	(31.3-161.0)
Larynx				
Male	5	4.2	117.7	(37.9-274.7)
Female	2	1.3	nc	(nc-nc)
Leukemia				
Male	9	11.3	79.6	(36.3-151.1)
Female	10	8.3	121.2	(58.0-222.8)
Liver and Intrahepatic Bile Ducts				
Male	9	10.1	89.4	(40.8-169.8)
Female	3	3.4	nc	(nc-nc)
Lung and Bronchus				
Male	41	49.7	82.5	(59.2-111.9)
Female	45	53.7	83.8	(61.1-112.2)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	21	18.0	116.9	(72.3-178.6)
Female	12	13.8	86.8	(44.8-151.7)
Multiple Myeloma				
Male	6	5.7	104.6	(38.2-227.7)
Female	6	4.7	127.2	(46.4-276.8)
Non-Hodgkin Lymphoma				
Male	15	16.1	93.2	(52.1-153.7)
Female	9	14.5	62.3	(28.4-118.2)
Oral Cavity & Pharynx				
Male	9	13.8	65.2	(29.8-123.8)
Female	6	6.0	99.3	(36.3-216.2)
Ovary				
Female	13	9.7	133.9	(71.2-229.0)
Pancreas				
Male	11	10.1	108.6	(54.1-194.3)
Female	12	10.5	113.8	(58.7-198.8)
Prostate				
Male	119	90.8	131.0	(108.6-156.8)
Stomach				
Male	7	6.8	102.8	(41.2-211.9)
Female	3	4.1	nc	(nc-nc)
Testis				
Male	5	3.5	143.3	(46.2-334.4)
Thyroid				
Male	4	7.2	nc	(nc-nc)
Female	21	19.8	106.3	(65.8-162.5)
Uteri Corpus and Uterus, NOS				
Female	25	25.1	99.5	(64.3-146.8)
All Sites / Types				
Male	379	366.8	103.3	(93.2-114.3)
Female	394	380.4	103.6	(93.6-114.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	62	54.1	114.6	(87.9-147.0)
Female	20	20.5	97.6	(59.6-150.7)
Brain and Other Nervous System				
Male	15	11.7	128.4	(71.8-211.7)
Female	12	9.6	125.5	(64.8-219.2)
Breast				
Male	2	1.9	nc	(nc-nc)
Female	229	223.3	102.6	(89.7-116.7)
Cervix Uteri				
Female	9	8.1	111.0	(50.6-210.7)
Colon / Rectum				
Male	63	58.9	106.9	(82.1-136.8)
Female	59	60.2	98.1	(74.7-126.5)
Esophagus				
Male	7	13.9	50.3	(20.2-103.7)
Female	5	4.0	125.1	(40.3-292.1)
Hodgkin Lymphoma				
Male	5	5.8	86.7	(27.9-202.3)
Female	5	4.8	104.7	(33.7-244.3)
Kidney & Renal Pelvis				
Male	37	30.9	119.7	(84.3-165.0)
Female	21	18.0	116.8	(72.3-178.6)
Larynx				
Male	6	8.1	74.1	(27.0-161.2)
Female	3	2.5	nc	(nc-nc)
Leukemia				
Male	19	23.1	82.3	(49.5-128.5)
Female	15	17.4	86.2	(48.2-142.1)
Liver and Intrahepatic Bile Ducts				
Male	27	18.8	143.2	(94.4-208.4)
Female	4	6.7	nc	(nc-nc)
Lung and Bronchus				
Male	103	96.5	106.8	(87.1-129.5)
Female	100	106.2	94.2	(76.6-114.5)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	24	35.9	66.9	(42.9-99.6)
Female	13	29.8	43.6	(23.2-74.6)
Multiple Myeloma				
Male	11	11.1	99.1	(49.4-177.3)
Female	4	9.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	23	32.2	71.4	(45.2-107.1)
Female	34	29.1	117.0	(81.0-163.5)
Oral Cavity & Pharynx				
Male	17	26.0	65.3	(38.0-104.6)
Female	8	12.1	66.0	(28.4-130.1)
Ovary				
Female	19	19.7	96.4	(58.0-150.6)
Pancreas				
Male	25	19.3	129.3	(83.7-190.9)
Female	26	21.0	124.0	(81.0-181.7)
Prostate				
Male	140	167.9	83.4	(70.1-98.4)
Stomach				
Male	18	13.2	136.5	(80.9-215.8)
Female	10	8.2	122.2	(58.5-224.7)
Testis				
Male	13	11.6	112.4	(59.8-192.1)
Thyroid				
Male	17	15.6	109.2	(63.6-174.8)
Female	47	46.8	100.4	(73.8-133.6)
Uteri Corpus and Uterus, NOS				
Female	41	49.7	82.5	(59.2-111.9)
All Sites / Types				
Male	685	714.5	95.9	(88.8-103.3)
Female	747	769.9	97.0	(90.2-104.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	7	10.8	65.1	(26.1-134.1)
Female	2	3.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	2.2	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)
Breast				
Male	0	0.4	nc	(nc-nc)
Female	34	44.8	75.9	(52.5-106.1)
Cervix Uteri				
Female	1	1.5	nc	(nc-nc)
Colon / Rectum				
Male	17	11.9	142.9	(83.2-228.8)
Female	14	10.8	130.1	(71.1-218.4)
Esophagus				
Male	1	2.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	5	6.3	78.8	(25.4-183.8)
Female	8	3.5	231.4	(99.6-455.9)
Larynx				
Male	2	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Leukemia				
Male	2	4.4	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	5	4.0	125.9	(40.6-293.8)
Female	2	1.2	nc	(nc-nc)
Lung and Bronchus				
Male	20	19.4	103.3	(63.1-159.5)
Female	20	20.0	99.8	(60.9-154.1)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	3	6.9	nc	(nc-nc)
Female	4	5.3	nc	(nc-nc)
Multiple Myeloma				
Male	2	2.3	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	10	6.3	158.6	(75.9-291.8)
Female	6	5.2	114.8	(41.9-249.8)
Oral Cavity & Pharynx				
Male	4	5.5	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)
Ovary				
Female	5	3.8	132.1	(42.6-308.3)
Pancreas				
Male	8	3.9	203.0	(87.4-400.1)
Female	6	3.7	161.1	(58.8-350.6)
Prostate				
Male	26	37.5	69.4	(45.3-101.7)
Stomach				
Male	2	2.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)
Testis				
Male	2	1.5	nc	(nc-nc)
Thyroid				
Male	2	2.8	nc	(nc-nc)
Female	4	8.3	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	9	10.1	89.2	(40.7-169.3)
All Sites / Types				
Male	133	145.3	91.6	(76.7-108.5)
Female	138	144.8	95.3	(80.1-112.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	36	29.0	124.3	(87.0-172.1)
Female	16	10.1	158.3	(90.4-257.1)
Brain and Other Nervous System				
Male	10	5.1	196.3	(94.0-361.0)
Female	2	4.3	nc	(nc-nc)
Breast				
Male	0	1.0	nc	(nc-nc)
Female	93	113.3	82.1	(66.2-100.5)
Cervix Uteri				
Female	2	3.6	nc	(nc-nc)
Colon / Rectum				
Male	32	30.4	105.4	(72.1-148.7)
Female	41	29.3	140.2	(100.6-190.1)
Esophagus				
Male	7	7.2	96.6	(38.7-199.0)
Female	2	2.0	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	1.9	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	16	15.1	105.6	(60.3-171.6)
Female	16	9.0	177.1	(101.1-287.6)
Larynx				
Male	5	4.3	117.2	(37.8-273.5)
Female	4	1.3	nc	(nc-nc)
Leukemia				
Male	12	11.1	107.6	(55.6-188.0)
Female	14	8.0	175.5	(95.8-294.4)
Liver and Intrahepatic Bile Ducts				
Male	14	9.7	144.3	(78.8-242.2)
Female	6	3.4	179.0	(65.4-389.6)
Lung and Bronchus				
Male	74	51.7	143.1	(112.4-179.7)
Female	81	54.1	149.7	(118.8-186.0)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	14	17.9	78.3	(42.7-131.3)
Female	14	13.6	102.7	(56.1-172.3)
Multiple Myeloma				
Male	11	5.8	188.4	(93.9-337.2)
Female	4	4.6	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	20	15.9	125.5	(76.6-193.8)
Female	9	14.1	64.0	(29.2-121.4)
Oral Cavity & Pharynx				
Male	16	12.9	124.0	(70.8-201.4)
Female	6	6.0	100.6	(36.7-218.9)
Ovary				
Female	7	9.7	72.1	(28.9-148.6)
Pancreas				
Male	12	10.2	118.1	(61.0-206.4)
Female	17	10.2	167.2	(97.3-267.7)
Prostate				
Male	90	85.4	105.3	(84.7-129.5)
Stomach				
Male	5	6.9	72.5	(23.4-169.2)
Female	3	3.9	nc	(nc-nc)
Testis				
Male	4	3.2	nc	(nc-nc)
Thyroid				
Male	6	6.5	92.4	(33.7-201.1)
Female	17	19.6	86.6	(50.4-138.7)
Uteri Corpus and Uterus, NOS				
Female	21	25.7	81.8	(50.6-125.1)
All Sites / Types				
Male	420	360.7	116.4	(105.6-128.1)
Female	407	377.2	107.9	(97.7-118.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	6	5.4	110.2	(40.3-239.9)
Female	1	1.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	13	20.7	62.8	(33.4-107.5)
Cervix Uteri				
Female	1	0.7	nc	(nc-nc)
Colon / Rectum				
Male	7	6.1	114.1	(45.7-235.0)
Female	6	4.7	126.5	(46.2-275.3)
Esophagus				
Male	3	1.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	5	3.2	157.0	(50.6-366.4)
Female	1	1.6	nc	(nc-nc)
Larynx				
Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	3	2.2	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	2	1.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Lung and Bronchus				
Male	10	9.7	103.2	(49.4-189.8)
Female	9	9.0	99.9	(45.6-189.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	2	3.5	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)
Multiple Myeloma				
Male	4	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	3.2	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	2.8	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Ovary				
Female	0	1.7	nc	(nc-nc)
Pancreas				
Male	7	2.0	353.9	(141.8-729.2)
Female	0	1.6	nc	(nc-nc)
Prostate				
Male	12	18.6	64.7	(33.4-113.0)
Stomach				
Male	1	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Testis				
Male	4	0.8	nc	(nc-nc)
Thyroid				
Male	0	1.5	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	5	4.5	110.0	(35.5-256.7)
All Sites / Types				
Male	71	73.0	97.2	(75.9-122.7)
Female	47	65.9	71.3	(52.4-94.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	0	1.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)
Breast				
Male	0	0.0	nc	(nc-nc)
Female	2	4.7	nc	(nc-nc)
Cervix Uteri				
Female	0	0.1	nc	(nc-nc)
Colon / Rectum				
Male	1	1.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)
Esophagus				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Larynx				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Lung and Bronchus				
Male	3	2.4	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	0.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Multiple Myeloma				
Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Ovary				
Female	2	0.4	nc	(nc-nc)
Pancreas				
Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Prostate				
Male	6	4.2	143.1	(52.3-311.5)
Stomach				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	0	0.1	nc	(nc-nc)
Thyroid				
Male	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	1	1.2	nc	(nc-nc)
All Sites / Types				
Male	12	16.4	73.2	(37.8-127.8)
Female	14	15.6	89.6	(49.0-150.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Breast				
Male	0	0.0	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)
Cervix Uteri				
Female	0	0.1	nc	(nc-nc)
Colon / Rectum				
Male	0	1.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Esophagus				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Larynx				
Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Leukemia				
Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)
Lung and Bronchus				
Male	1	1.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Ovary				
Female	1	0.3	nc	(nc-nc)
Pancreas				
Male	0	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Prostate				
Male	2	3.7	nc	(nc-nc)
Stomach				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Testis				
Male	0	0.1	nc	(nc-nc)
Thyroid				
Male	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	0	0.8	nc	(nc-nc)
All Sites / Types				
Male	5	13.0	38.5	(12.4-89.9)
Female	10	10.4	95.8	(45.9-176.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	30	29.9	100.4	(67.7-143.3)
Female	10	12.9	77.4	(37.1-142.3)
Brain and Other Nervous System				
Male	10	6.4	156.2	(74.8-287.2)
Female	8	5.7	141.2	(60.8-278.3)
Breast				
Male	2	1.1	nc	(nc-nc)
Female	140	143.5	97.5	(82.1-115.1)
Cervix Uteri				
Female	10	5.2	191.8	(91.8-352.7)
Colon / Rectum				
Male	39	33.9	114.9	(81.7-157.1)
Female	35	37.3	93.9	(65.4-130.6)
Esophagus				
Male	7	7.8	90.0	(36.1-185.4)
Female	1	2.6	nc	(nc-nc)
Hodgkin Lymphoma				
Male	5	2.8	177.0	(57.0-413.0)
Female	3	2.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	15	17.7	84.5	(47.3-139.4)
Female	2	11.4	nc	(nc-nc)
Larynx				
Male	6	4.6	129.9	(47.4-282.7)
Female	0	1.6	nc	(nc-nc)
Leukemia				
Male	15	12.7	118.2	(66.1-195.0)
Female	12	10.4	115.6	(59.7-202.0)
Liver and Intrahepatic Bile Ducts				
Male	8	10.7	74.7	(32.1-147.1)
Female	4	4.2	nc	(nc-nc)
Lung and Bronchus				
Male	51	53.4	95.5	(71.1-125.5)
Female	66	68.9	95.8	(74.1-121.9)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	12	20.2	59.5	(30.7-103.9)
Female	22	18.5	118.7	(74.4-179.7)
Multiple Myeloma				
Male	4	6.4	nc	(nc-nc)
Female	5	5.9	84.3	(27.2-196.8)
Non-Hodgkin Lymphoma				
Male	19	18.2	104.7	(63.0-163.5)
Female	17	18.3	92.9	(54.1-148.7)
Oral Cavity & Pharynx				
Male	13	14.9	87.3	(46.4-149.3)
Female	9	7.6	117.9	(53.8-223.9)
Ovary				
Female	15	12.4	120.6	(67.4-198.9)
Pancreas				
Male	11	10.8	101.5	(50.6-181.7)
Female	19	13.1	145.2	(87.4-226.7)
Prostate				
Male	68	93.0	73.2	(56.8-92.7)
Stomach				
Male	9	7.5	120.7	(55.1-229.2)
Female	10	5.0	199.3	(95.4-366.5)
Testis				
Male	6	5.8	102.8	(37.5-223.8)
Thyroid				
Male	8	8.9	89.9	(38.7-177.1)
Female	29	28.9	100.3	(67.2-144.0)
Uteri Corpus and Uterus, NOS				
Female	25	32.1	77.9	(50.4-115.0)
All Sites / Types				
Male	369	399.0	92.5	(83.3-102.4)
Female	480	486.7	98.6	(90.0-107.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	13	17.6	73.7	(39.2-126.0)
Female	5	6.5	76.8	(24.8-179.3)
Brain and Other Nervous System				
Male	1	3.1	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)
Breast				
Male	1	0.6	nc	(nc-nc)
Female	81	70.9	114.3	(90.8-142.0)
Cervix Uteri				
Female	2	2.1	nc	(nc-nc)
Colon / Rectum				
Male	13	18.6	69.8	(37.1-119.4)
Female	8	18.6	43.0	(18.5-84.8)
Esophagus				
Male	1	4.4	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	1.0	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	6	9.3	64.3	(23.5-140.1)
Female	4	5.7	nc	(nc-nc)
Larynx				
Male	0	2.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Leukemia				
Male	7	6.8	102.3	(41.0-210.9)
Female	2	5.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	2	5.9	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)
Lung and Bronchus				
Male	18	31.1	57.9	(34.3-91.5)
Female	19	34.8	54.6	(32.8-85.2)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	18	10.8	166.3	(98.5-262.9)
Female	13	8.3	157.4	(83.7-269.2)
Multiple Myeloma				
Male	4	3.6	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	7	9.7	72.0	(28.9-148.4)
Female	13	9.0	145.0	(77.2-248.1)
Oral Cavity & Pharynx				
Male	2	8.0	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)
Ovary				
Female	5	6.0	82.8	(26.7-193.2)
Pancreas				
Male	4	6.2	nc	(nc-nc)
Female	8	6.5	122.8	(52.9-241.9)
Prostate				
Male	62	53.2	116.5	(89.3-149.3)
Stomach				
Male	2	4.2	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)
Testis				
Male	3	1.6	nc	(nc-nc)
Thyroid				
Male	5	3.9	126.7	(40.8-295.6)
Female	11	11.2	98.1	(48.9-175.6)
Uteri Corpus and Uterus, NOS				
Female	13	16.0	81.1	(43.2-138.7)
All Sites / Types				
Male	185	220.4	83.9	(72.3-96.9)
Female	204	236.5	86.3	(74.8-98.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	27	20.4	132.1	(87.0-192.2)
Female	6	7.6	78.9	(28.8-171.8)
Brain and Other Nervous System				
Male	4	3.6	nc	(nc-nc)
Female	0	3.2	nc	(nc-nc)
Breast				
Male	4	0.7	nc	(nc-nc)
Female	83	76.8	108.1	(86.1-134.1)
Cervix Uteri				
Female	4	2.6	nc	(nc-nc)
Colon / Rectum				
Male	21	21.6	97.0	(60.0-148.3)
Female	22	22.3	98.6	(61.7-149.2)
Esophagus				
Male	9	5.0	178.3	(81.3-338.4)
Female	2	1.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	3	1.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	10	10.7	93.7	(44.9-172.4)
Female	11	6.3	175.8	(87.7-314.6)
Larynx				
Male	6	2.9	207.0	(75.6-450.6)
Female	2	0.9	nc	(nc-nc)
Leukemia				
Male	11	7.9	139.2	(69.4-249.1)
Female	5	6.1	82.1	(26.4-191.5)
Liver and Intrahepatic Bile Ducts				
Male	9	6.7	134.6	(61.4-255.6)
Female	5	2.4	211.3	(68.1-493.0)
Lung and Bronchus				
Male	43	35.7	120.3	(87.1-162.1)
Female	50	38.2	130.8	(97.1-172.5)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	11	12.5	88.2	(44.0-157.8)
Female	7	9.8	71.5	(28.6-147.3)
Multiple Myeloma				
Male	4	4.0	nc	(nc-nc)
Female	7	3.3	209.1	(83.8-430.8)
Non-Hodgkin Lymphoma				
Male	10	11.2	89.5	(42.8-164.6)
Female	9	10.3	87.8	(40.0-166.6)
Oral Cavity & Pharynx				
Male	12	9.1	132.5	(68.4-231.4)
Female	5	4.2	118.2	(38.1-275.9)
Ovary				
Female	12	6.7	179.7	(92.7-313.9)
Pancreas				
Male	7	7.1	98.7	(39.6-203.4)
Female	6	7.8	76.8	(28.0-167.1)
Prostate				
Male	56	60.2	93.0	(70.2-120.7)
Stomach				
Male	3	4.8	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)
Testis				
Male	3	2.5	nc	(nc-nc)
Thyroid				
Male	6	4.7	128.6	(47.0-280.0)
Female	16	14.0	114.1	(65.2-185.3)
Uteri Corpus and Uterus, NOS				
Female	19	16.5	115.1	(69.2-179.7)
All Sites / Types				
Male	287	253.5	113.2	(100.5-127.1)
Female	302	267.7	112.8	(100.5-126.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	19	29.5	64.5	(38.8-100.7)
Female	6	9.9	60.6	(22.1-131.8)
Brain and Other Nervous System				
Male	2	5.5	nc	(nc-nc)
Female	5	4.9	102.2	(32.9-238.4)
Breast				
Male	0	1.0	nc	(nc-nc)
Female	142	110.5	128.5	(108.3-151.5)
Cervix Uteri				
Female	2	3.6	nc	(nc-nc)
Colon / Rectum				
Male	22	31.6	69.7	(43.7-105.5)
Female	26	29.4	88.6	(57.8-129.8)
Esophagus				
Male	1	7.5	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	1.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	14	16.0	87.7	(47.9-147.1)
Female	5	8.8	57.0	(18.4-133.0)
Larynx				
Male	3	4.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Leukemia				
Male	13	11.9	109.6	(58.3-187.4)
Female	13	8.4	154.1	(82.0-263.5)
Liver and Intrahepatic Bile Ducts				
Male	4	9.9	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)
Lung and Bronchus				
Male	17	51.7	32.9	(19.1-52.6)
Female	34	51.8	65.6	(45.4-91.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	28	18.2	154.0	(102.3-222.5)
Female	27	13.7	197.1	(129.9-286.8)
Multiple Myeloma				
Male	5	6.0	84.0	(27.1-195.9)
Female	6	4.5	134.0	(48.9-291.7)
Non-Hodgkin Lymphoma				
Male	13	16.5	78.9	(42.0-134.9)
Female	10	14.0	71.4	(34.2-131.4)
Oral Cavity & Pharynx				
Male	10	13.6	73.6	(35.2-135.4)
Female	5	5.9	84.9	(27.4-198.2)
Ovary				
Female	11	9.6	115.0	(57.3-205.7)
Pancreas				
Male	11	10.4	105.9	(52.8-189.5)
Female	11	10.0	109.7	(54.7-196.4)
Prostate				
Male	115	90.2	127.6	(105.3-153.1)
Stomach				
Male	5	7.0	71.3	(23.0-166.4)
Female	1	4.0	nc	(nc-nc)
Testis				
Male	3	3.0	nc	(nc-nc)
Thyroid				
Male	8	6.9	116.6	(50.2-229.7)
Female	20	21.1	94.6	(57.8-146.1)
Uteri Corpus and Uterus, NOS				
Female	21	24.0	87.6	(54.2-133.9)
All Sites / Types				
Male	313	372.8	83.9	(74.9-93.8)
Female	384	373.4	102.8	(92.8-113.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	7	7.5	93.0	(37.3-191.7)
Female	2	2.9	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	1.0	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	23	25.1	91.8	(58.2-137.7)
Cervix Uteri				
Female	0	0.6	nc	(nc-nc)
Colon / Rectum				
Male	6	7.0	86.1	(31.4-187.3)
Female	5	7.5	66.5	(21.4-155.2)
Esophagus				
Male	1	1.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	2	3.5	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)
Larynx				
Male	4	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Leukemia				
Male	3	2.6	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	2.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Lung and Bronchus				
Male	4	13.8	nc	(nc-nc)
Female	12	15.1	79.3	(40.9-138.6)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	4	4.2	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)
Multiple Myeloma				
Male	0	1.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	6	3.7	161.8	(59.1-352.2)
Female	1	3.5	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	3	2.9	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)
Ovary				
Female	2	2.2	nc	(nc-nc)
Pancreas				
Male	0	2.5	nc	(nc-nc)
Female	5	2.9	171.5	(55.3-400.2)
Prostate				
Male	19	22.1	85.9	(51.7-134.1)
Stomach				
Male	0	1.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Testis				
Male	0	0.3	nc	(nc-nc)
Thyroid				
Male	0	1.2	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	4	5.9	nc	(nc-nc)
All Sites / Types				
Male	66	88.0	75.0	(58.0-95.4)
Female	71	90.2	78.7	(61.5-99.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	0	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Breast				
Male	0	0.0	nc	(nc-nc)
Female	1	4.5	nc	(nc-nc)
Cervix Uteri				
Female	0	0.1	nc	(nc-nc)
Colon / Rectum				
Male	1	1.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Esophagus				
Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	0.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Larynx				
Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Leukemia				
Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Lung and Bronchus				
Male	3	2.5	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Ovary				
Female	0	0.4	nc	(nc-nc)
Pancreas				
Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Prostate				
Male	2	5.3	nc	(nc-nc)
Stomach				
Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Testis				
Male	0	0.1	nc	(nc-nc)
Thyroid				
Male	0	0.3	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	2	1.1	nc	(nc-nc)
All Sites / Types				
Male	11	19.4	56.8	(28.3-101.6)
Female	9	14.0	64.2	(29.3-122.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	7	5.3	133.0	(53.3-274.0)
Female	1	1.8	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	25	18.5	135.2	(87.5-199.6)
Cervix Uteri				
Female	1	0.6	nc	(nc-nc)
Colon / Rectum				
Male	1	5.4	nc	(nc-nc)
Female	9	5.3	170.5	(77.8-323.7)
Esophagus				
Male	3	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	2.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Larynx				
Male	0	0.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)
Leukemia				
Male	1	2.1	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	1.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Lung and Bronchus				
Male	4	9.2	nc	(nc-nc)
Female	11	9.2	119.5	(59.6-213.9)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	5	3.1	158.8	(51.2-370.6)
Female	7	2.4	296.1	(118.6-610.2)
Multiple Myeloma				
Male	0	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	4	2.9	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	3	2.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)
Ovary				
Female	0	1.7	nc	(nc-nc)
Pancreas				
Male	2	1.8	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)
Prostate				
Male	21	14.0	149.9	(92.7-229.1)
Stomach				
Male	0	1.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Testis				
Male	0	0.6	nc	(nc-nc)
Thyroid				
Male	2	1.1	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	8	4.1	195.7	(84.3-385.6)
All Sites / Types				
Male	61	63.0	96.8	(74.0-124.3)
Female	80	64.5	123.9	(98.3-154.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	19	8.5	223.3	(134.4-348.7)
Female	3	3.2	nc	(nc-nc)
Brain and Other Nervous System				
Male	3	1.8	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)
Breast				
Male	1	0.3	nc	(nc-nc)
Female	26	30.0	86.7	(56.6-127.0)
Cervix Uteri				
Female	1	0.9	nc	(nc-nc)
Colon / Rectum				
Male	5	9.2	54.1	(17.4-126.2)
Female	5	9.2	54.3	(17.5-126.8)
Esophagus				
Male	2	2.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	8	4.9	163.0	(70.2-321.1)
Female	3	2.5	nc	(nc-nc)
Larynx				
Male	1	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Leukemia				
Male	3	3.6	nc	(nc-nc)
Female	5	2.4	205.0	(66.1-478.3)
Liver and Intrahepatic Bile Ducts				
Male	1	3.0	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Lung and Bronchus				
Male	25	15.1	165.2	(106.9-243.9)
Female	16	15.8	101.0	(57.7-164.0)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	6	5.7	106.2	(38.8-231.1)
Female	2	3.8	nc	(nc-nc)
Multiple Myeloma				
Male	1	1.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	4	5.1	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	4	4.2	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)
Ovary				
Female	6	2.7	224.6	(82.0-489.0)
Pancreas				
Male	2	3.1	nc	(nc-nc)
Female	6	3.3	180.6	(65.9-393.0)
Prostate				
Male	28	27.6	101.4	(67.4-146.6)
Stomach				
Male	1	2.1	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)
Testis				
Male	2	1.9	nc	(nc-nc)
Thyroid				
Male	1	2.5	nc	(nc-nc)
Female	11	4.8	231.5	(115.4-414.3)
Uteri Corpus and Uterus, NOS				
Female	4	6.8	nc	(nc-nc)
All Sites / Types				
Male	133	114.0	116.6	(97.7-138.2)
Female	111	107.0	103.7	(85.3-124.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	9	8.5	106.4	(48.6-202.0)
Female	3	2.7	nc	(nc-nc)
Brain and Other Nervous System				
Male	5	1.6	319.9	(103.1-746.5)
Female	2	1.2	nc	(nc-nc)
Breast				
Male	0	0.3	nc	(nc-nc)
Female	38	30.8	123.5	(87.4-169.5)
Cervix Uteri				
Female	1	1.0	nc	(nc-nc)
Colon / Rectum				
Male	7	9.1	77.2	(30.9-159.1)
Female	17	8.0	212.6	(123.8-340.4)
Esophagus				
Male	5	2.2	229.9	(74.1-536.5)
Female	1	0.5	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	4	4.6	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)
Larynx				
Male	1	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Leukemia				
Male	0	3.3	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	2	2.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Lung and Bronchus				
Male	18	15.0	120.1	(71.1-189.8)
Female	19	14.2	134.1	(80.7-209.4)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	10	5.3	189.4	(90.7-348.4)
Female	4	3.7	nc	(nc-nc)
Multiple Myeloma				
Male	0	1.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	8	4.8	167.8	(72.2-330.6)
Female	9	3.8	234.5	(107.0-445.3)
Oral Cavity & Pharynx				
Male	6	3.9	152.7	(55.7-332.3)
Female	2	1.6	nc	(nc-nc)
Ovary				
Female	1	2.6	nc	(nc-nc)
Pancreas				
Male	1	3.0	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)
Prostate				
Male	21	26.6	79.0	(48.9-120.8)
Stomach				
Male	2	2.0	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)
Testis				
Male	3	1.0	nc	(nc-nc)
Thyroid				
Male	2	2.0	nc	(nc-nc)
Female	11	5.5	201.1	(100.2-359.8)
Uteri Corpus and Uterus, NOS				
Female	4	7.0	nc	(nc-nc)
All Sites / Types				
Male	111	108.3	102.5	(84.3-123.4)
Female	129	102.5	125.9	(105.1-149.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	3	5.3	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	0.9	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	15	16.7	89.6	(50.1-147.8)
Cervix Uteri				
Female	0	0.5	nc	(nc-nc)
Colon / Rectum				
Male	3	5.5	nc	(nc-nc)
Female	2	4.6	nc	(nc-nc)
Esophagus				
Male	1	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	3	2.8	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)
Larynx				
Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	1	2.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	4	1.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Lung and Bronchus				
Male	7	9.2	75.9	(30.4-156.3)
Female	14	8.4	166.1	(90.7-278.6)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	5	3.2	154.7	(49.8-361.0)
Female	2	2.1	nc	(nc-nc)
Multiple Myeloma				
Male	0	1.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	2.9	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	2.4	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)
Ovary				
Female	4	1.5	nc	(nc-nc)
Pancreas				
Male	0	1.8	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)
Prostate				
Male	13	16.0	81.1	(43.1-138.6)
Stomach				
Male	2	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Testis				
Male	0	0.6	nc	(nc-nc)
Thyroid				
Male	0	1.2	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	6	3.9	153.7	(56.1-334.4)
All Sites / Types				
Male	50	66.1	75.7	(56.2-99.8)
Female	58	58.2	99.7	(75.7-128.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	7	4.4	159.8	(64.0-329.3)
Female	0	1.5	nc	(nc-nc)
Brain and Other Nervous System				
Male	2	1.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	23	18.6	123.8	(78.4-185.7)
Cervix Uteri				
Female	0	0.6	nc	(nc-nc)
Colon / Rectum				
Male	4	5.1	nc	(nc-nc)
Female	1	4.4	nc	(nc-nc)
Esophagus				
Male	0	1.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	6	2.7	218.4	(79.7-475.3)
Female	1	1.4	nc	(nc-nc)
Larynx				
Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	1	1.9	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	1.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Lung and Bronchus				
Male	1	7.9	nc	(nc-nc)
Female	4	7.9	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	2	3.0	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)
Multiple Myeloma				
Male	3	1.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	3	2.7	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	2.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Ovary				
Female	1	1.6	nc	(nc-nc)
Pancreas				
Male	2	1.7	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Prostate				
Male	21	16.0	131.5	(81.4-201.0)
Stomach				
Male	2	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Testis				
Male	0	0.6	nc	(nc-nc)
Thyroid				
Male	0	1.3	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	3	4.3	nc	(nc-nc)
All Sites / Types				
Male	59	61.5	95.9	(73.0-123.7)
Female	47	59.3	79.3	(58.2-105.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	36	30.2	119.1	(83.4-164.9)
Female	8	11.9	67.2	(28.9-132.4)
Brain and Other Nervous System				
Male	7	6.0	116.8	(46.8-240.7)
Female	6	5.1	118.3	(43.2-257.4)
Breast				
Male	0	1.0	nc	(nc-nc)
Female	105	126.1	83.3	(68.1-100.8)
Cervix Uteri				
Female	9	4.2	215.1	(98.2-408.4)
Colon / Rectum				
Male	43	32.0	134.4	(97.3-181.1)
Female	42	34.5	121.9	(87.8-164.8)
Esophagus				
Male	12	7.8	153.3	(79.1-267.8)
Female	1	2.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	2.4	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	16	16.8	95.5	(54.6-155.1)
Female	10	10.2	97.9	(46.9-180.1)
Larynx				
Male	4	4.6	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)
Leukemia				
Male	11	12.4	88.4	(44.1-158.2)
Female	11	9.6	115.1	(57.4-206.0)
Liver and Intrahepatic Bile Ducts				
Male	12	10.6	113.2	(58.4-197.7)
Female	4	3.8	nc	(nc-nc)
Lung and Bronchus				
Male	49	54.2	90.4	(66.9-119.6)
Female	81	61.7	131.2	(104.2-163.1)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	14	19.2	73.0	(39.9-122.5)
Female	11	15.9	69.2	(34.5-123.8)
Multiple Myeloma				
Male	2	6.2	nc	(nc-nc)
Female	4	5.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	20	17.2	116.2	(70.9-179.4)
Female	13	16.3	79.6	(42.3-136.1)
Oral Cavity & Pharynx				
Male	16	14.2	112.6	(64.3-182.9)
Female	6	6.8	88.5	(32.3-192.6)
Ovary				
Female	7	10.9	64.1	(25.7-132.0)
Pancreas				
Male	12	10.8	111.6	(57.6-194.9)
Female	8	12.1	66.3	(28.6-130.7)
Prostate				
Male	79	95.4	82.8	(65.6-103.2)
Stomach				
Male	5	7.3	69.0	(22.2-160.9)
Female	5	4.7	107.1	(34.5-250.0)
Testis				
Male	6	4.3	139.1	(50.8-302.7)
Thyroid				
Male	12	7.5	160.1	(82.6-279.7)
Female	25	23.1	108.2	(70.0-159.7)
Uteri Corpus and Uterus, NOS				
Female	24	27.9	86.1	(55.1-128.1)
All Sites / Types				
Male	386	391.5	98.6	(89.0-108.9)
Female	423	431.5	98.0	(88.9-107.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	2	1.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	5	7.4	67.2	(21.6-156.8)
Cervix Uteri				
Female	0	0.2	nc	(nc-nc)
Colon / Rectum				
Male	0	2.0	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)
Esophagus				
Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	1.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Larynx				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	0	0.7	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	7	3.5	201.6	(80.8-415.4)
Female	0	3.6	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	2	1.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Multiple Myeloma				
Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	4	1.1	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Ovary				
Female	0	0.6	nc	(nc-nc)
Pancreas				
Male	1	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Prostate				
Male	9	6.7	134.0	(61.1-254.3)
Stomach				
Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	0	0.2	nc	(nc-nc)
Thyroid				
Male	1	0.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	2	1.8	nc	(nc-nc)
All Sites / Types				
Male	34	25.1	135.4	(93.8-189.3)
Female	17	24.3	70.0	(40.8-112.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	7	2.0	349.8	(140.1-720.8)
Female	0	1.2	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	23	14.9	154.1	(97.6-231.2)
Cervix Uteri				
Female	0	0.5	nc	(nc-nc)
Colon / Rectum				
Male	3	2.3	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)
Esophagus				
Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	4	1.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)
Larynx				
Male	2	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	1	0.9	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Lung and Bronchus				
Male	1	3.9	nc	(nc-nc)
Female	6	6.1	98.2	(35.8-213.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	4	1.3	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)
Multiple Myeloma				
Male	2	0.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	3	1.2	nc	(nc-nc)
Female	4	1.8	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	1.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Ovary				
Female	2	1.3	nc	(nc-nc)
Pancreas				
Male	0	0.8	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)
Prostate				
Male	14	8.5	164.3	(89.8-275.7)
Stomach				
Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Testis				
Male	1	0.3	nc	(nc-nc)
Thyroid				
Male	2	0.6	nc	(nc-nc)
Female	0	2.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	4	3.6	nc	(nc-nc)
All Sites / Types				
Male	47	29.6	158.7	(116.6-211.0)
Female	55	48.7	112.9	(85.0-146.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	13	17.8	73.1	(38.9-124.9)
Female	8	6.9	115.7	(49.8-228.0)
Brain and Other Nervous System				
Male	3	3.7	nc	(nc-nc)
Female	6	3.2	190.4	(69.5-414.5)
Breast				
Male	1	0.6	nc	(nc-nc)
Female	79	78.1	101.2	(80.1-126.1)
Cervix Uteri				
Female	1	2.6	nc	(nc-nc)
Colon / Rectum				
Male	19	20.4	93.1	(56.0-145.4)
Female	19	21.0	90.4	(54.4-141.2)
Esophagus				
Male	3	4.7	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	3	1.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	4	10.5	nc	(nc-nc)
Female	1	6.1	nc	(nc-nc)
Larynx				
Male	1	2.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Leukemia				
Male	11	7.5	147.0	(73.3-263.0)
Female	9	5.8	155.6	(71.0-295.4)
Liver and Intrahepatic Bile Ducts				
Male	5	6.5	77.4	(24.9-180.6)
Female	2	2.3	nc	(nc-nc)
Lung and Bronchus				
Male	20	31.4	63.7	(38.9-98.5)
Female	28	35.1	79.7	(53.0-115.2)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	12	11.9	101.2	(52.2-176.8)
Female	6	9.8	61.4	(22.4-133.6)
Multiple Myeloma				
Male	6	3.8	158.8	(58.0-345.6)
Female	3	3.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	9	10.6	84.5	(38.6-160.4)
Female	6	9.8	61.4	(22.4-133.6)
Oral Cavity & Pharynx				
Male	9	9.1	99.2	(45.3-188.4)
Female	3	4.2	nc	(nc-nc)
Ovary				
Female	5	6.7	74.3	(24.0-173.5)
Pancreas				
Male	6	6.5	92.8	(33.9-202.0)
Female	10	7.2	138.9	(66.5-255.4)
Prostate				
Male	51	55.8	91.4	(68.1-120.2)
Stomach				
Male	5	4.4	113.3	(36.5-264.3)
Female	3	2.9	nc	(nc-nc)
Testis				
Male	4	2.9	nc	(nc-nc)
Thyroid				
Male	7	5.1	137.0	(54.9-282.3)
Female	13	14.6	88.8	(47.2-151.9)
Uteri Corpus and Uterus, NOS				
Female	20	17.0	117.6	(71.8-181.7)
All Sites / Types				
Male	213	236.5	90.1	(78.4-103.0)
Female	245	261.4	93.7	(82.3-106.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	43	43.1	99.8	(72.2-134.4)
Female	14	14.5	96.4	(52.7-161.8)
Brain and Other Nervous System				
Male	4	8.5	nc	(nc-nc)
Female	6	6.8	88.4	(32.3-192.5)
Breast				
Male	3	1.5	nc	(nc-nc)
Female	198	164.0	120.7	(104.5-138.8)
Cervix Uteri				
Female	8	5.4	148.8	(64.1-293.3)
Colon / Rectum				
Male	63	46.2	136.3	(104.7-174.4)
Female	51	42.4	120.2	(89.5-158.1)
Esophagus				
Male	14	11.1	126.0	(68.8-211.3)
Female	3	2.9	nc	(nc-nc)
Hodgkin Lymphoma				
Male	6	3.5	170.5	(62.3-371.1)
Female	0	3.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	21	23.8	88.1	(54.5-134.7)
Female	8	13.0	61.5	(26.5-121.2)
Larynx				
Male	4	6.4	nc	(nc-nc)
Female	4	1.8	nc	(nc-nc)
Leukemia				
Male	19	17.7	107.3	(64.6-167.6)
Female	9	12.1	74.5	(34.0-141.5)
Liver and Intrahepatic Bile Ducts				
Male	13	15.0	86.8	(46.2-148.5)
Female	4	4.9	nc	(nc-nc)
Lung and Bronchus				
Male	82	76.2	107.6	(85.5-133.5)
Female	80	76.8	104.1	(82.6-129.6)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	20	27.1	73.7	(45.0-113.8)
Female	20	20.5	97.4	(59.5-150.5)
Multiple Myeloma				
Male	10	8.8	114.1	(54.6-209.8)
Female	3	6.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	22	24.6	89.4	(56.0-135.3)
Female	21	20.6	101.7	(62.9-155.5)
Oral Cavity & Pharynx				
Male	17	20.4	83.5	(48.6-133.8)
Female	9	8.7	103.2	(47.1-195.8)
Ovary				
Female	19	14.3	133.3	(80.2-208.2)
Pancreas				
Male	13	15.3	84.8	(45.1-145.1)
Female	10	14.7	67.9	(32.5-124.9)
Prostate				
Male	122	136.5	89.3	(74.2-106.7)
Stomach				
Male	11	10.3	106.6	(53.1-190.7)
Female	8	5.8	138.2	(59.5-272.3)
Testis				
Male	7	6.1	114.5	(45.9-236.0)
Thyroid				
Male	6	10.7	56.0	(20.5-122.0)
Female	22	30.9	71.2	(44.6-107.7)
Uteri Corpus and Uterus, NOS				
Female	37	37.0	99.9	(70.3-137.7)
All Sites / Types				
Male	549	557.9	98.4	(90.3-107.0)
Female	566	551.0	102.7	(94.4-111.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	15	20.1	74.5	(41.7-122.9)
Female	4	6.4	nc	(nc-nc)
Brain and Other Nervous System				
Male	7	4.6	151.5	(60.7-312.3)
Female	5	3.6	140.3	(45.2-327.4)
Breast				
Male	1	0.8	nc	(nc-nc)
Female	105	90.9	115.5	(94.4-139.8)
Cervix Uteri				
Female	2	3.2	nc	(nc-nc)
Colon / Rectum				
Male	25	24.0	104.1	(67.3-153.6)
Female	25	19.9	125.6	(81.2-185.4)
Esophagus				
Male	4	5.9	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.7	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	10	13.5	73.8	(35.3-135.7)
Female	3	6.7	nc	(nc-nc)
Larynx				
Male	4	3.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Leukemia				
Male	10	8.8	113.0	(54.1-207.9)
Female	9	5.7	157.2	(71.7-298.5)
Liver and Intrahepatic Bile Ducts				
Male	6	8.3	72.3	(26.4-157.4)
Female	0	2.3	nc	(nc-nc)
Lung and Bronchus				
Male	32	38.1	84.1	(57.5-118.7)
Female	25	36.0	69.4	(44.9-102.4)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	13	14.2	91.6	(48.7-156.7)
Female	12	10.7	112.2	(57.9-196.0)
Multiple Myeloma				
Male	8	4.6	173.9	(74.9-342.6)
Female	3	3.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	13	12.8	102.0	(54.2-174.4)
Female	8	10.0	80.3	(34.6-158.1)
Oral Cavity & Pharynx				
Male	6	11.8	50.6	(18.5-110.2)
Female	3	4.4	nc	(nc-nc)
Ovary				
Female	6	7.5	79.5	(29.0-173.0)
Pancreas				
Male	9	7.8	116.0	(52.9-220.3)
Female	5	6.5	77.1	(24.8-179.8)
Prostate				
Male	83	76.7	108.2	(86.2-134.1)
Stomach				
Male	7	5.2	134.9	(54.0-277.9)
Female	1	2.7	nc	(nc-nc)
Testis				
Male	3	2.9	nc	(nc-nc)
Thyroid				
Male	10	6.4	155.4	(74.4-285.7)
Female	17	18.0	94.4	(55.0-151.2)
Uteri Corpus and Uterus, NOS				
Female	34	20.4	166.8	(115.5-233.1)
All Sites / Types				
Male	289	293.4	98.5	(87.5-110.5)
Female	292	282.2	103.5	(91.9-116.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	2	2.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	10	7.8	128.8	(61.7-236.9)
Cervix Uteri				
Female	0	0.3	nc	(nc-nc)
Colon / Rectum				
Male	1	2.2	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)
Esophagus				
Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Larynx				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	1	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	1	3.7	nc	(nc-nc)
Female	0	3.2	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	6	1.3	458.1	(167.3-997.1)
Female	0	0.9	nc	(nc-nc)
Multiple Myeloma				
Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	1.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	1.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Ovary				
Female	0	0.7	nc	(nc-nc)
Pancreas				
Male	0	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Prostate				
Male	10	7.3	137.9	(66.0-253.5)
Stomach				
Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	0	0.2	nc	(nc-nc)
Thyroid				
Male	0	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	1	1.8	nc	(nc-nc)
All Sites / Types				
Male	26	27.4	94.9	(62.0-139.1)
Female	14	24.4	57.4	(31.3-96.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	6	7.9	76.0	(27.7-165.4)
Female	3	2.3	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	1.6	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)
Breast				
Male	0	0.3	nc	(nc-nc)
Female	43	31.0	138.5	(100.2-186.6)
Cervix Uteri				
Female	0	1.1	nc	(nc-nc)
Colon / Rectum				
Male	7	9.2	76.3	(30.6-157.1)
Female	7	7.0	99.3	(39.8-204.7)
Esophagus				
Male	3	2.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	3	4.8	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)
Larynx				
Male	1	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Leukemia				
Male	4	3.3	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	3.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Lung and Bronchus				
Male	10	13.9	71.8	(34.4-132.1)
Female	14	12.3	113.7	(62.1-190.8)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	8	5.3	151.1	(65.0-297.6)
Female	6	3.7	160.9	(58.8-350.3)
Multiple Myeloma				
Male	1	1.7	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	6	4.8	126.2	(46.1-274.8)
Female	2	3.5	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	5	4.3	116.8	(37.6-272.5)
Female	3	1.6	nc	(nc-nc)
Ovary				
Female	3	2.6	nc	(nc-nc)
Pancreas				
Male	1	2.9	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)
Prostate				
Male	23	27.2	84.5	(53.6-126.8)
Stomach				
Male	2	2.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Testis				
Male	3	1.1	nc	(nc-nc)
Thyroid				
Male	1	2.3	nc	(nc-nc)
Female	7	6.0	116.6	(46.7-240.2)
Uteri Corpus and Uterus, NOS				
Female	8	7.3	109.7	(47.2-216.2)
All Sites / Types				
Male	98	108.2	90.6	(73.5-110.4)
Female	107	97.8	109.4	(89.7-132.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	18	15.3	117.8	(69.8-186.2)
Female	1	5.0	nc	(nc-nc)
Brain and Other Nervous System				
Male	4	2.7	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)
Breast				
Male	1	0.5	nc	(nc-nc)
Female	52	53.8	96.7	(72.2-126.8)
Cervix Uteri				
Female	1	1.6	nc	(nc-nc)
Colon / Rectum				
Male	12	15.6	76.8	(39.6-134.1)
Female	10	14.6	68.6	(32.9-126.2)
Esophagus				
Male	1	3.8	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	8	7.9	100.9	(43.4-198.8)
Female	1	4.3	nc	(nc-nc)
Larynx				
Male	1	2.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Leukemia				
Male	6	5.9	101.0	(36.9-219.8)
Female	6	4.1	147.2	(53.7-320.3)
Liver and Intrahepatic Bile Ducts				
Male	6	5.0	119.8	(43.7-260.7)
Female	0	1.7	nc	(nc-nc)
Lung and Bronchus				
Male	15	27.3	54.9	(30.7-90.5)
Female	17	26.3	64.8	(37.7-103.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	11	9.2	119.9	(59.8-214.6)
Female	9	6.5	138.8	(63.3-263.4)
Multiple Myeloma				
Male	3	3.0	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	10	8.2	122.0	(58.4-224.3)
Female	3	6.9	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	7	6.7	104.5	(41.9-215.3)
Female	0	2.9	nc	(nc-nc)
Ovary				
Female	2	4.7	nc	(nc-nc)
Pancreas				
Male	6	5.3	112.6	(41.1-245.0)
Female	11	5.1	214.5	(106.9-383.8)
Prostate				
Male	47	46.4	101.3	(74.5-134.8)
Stomach				
Male	2	3.6	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)
Testis				
Male	2	1.2	nc	(nc-nc)
Thyroid				
Male	7	3.2	218.6	(87.6-450.4)
Female	7	9.0	77.9	(31.2-160.5)
Uteri Corpus and Uterus, NOS				
Female	9	12.1	74.2	(33.8-140.8)
All Sites / Types				
Male	188	189.2	99.3	(85.7-114.6)
Female	146	182.7	79.9	(67.5-94.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	25	23.8	104.9	(67.8-154.8)
Female	7	7.1	98.1	(39.3-202.0)
Brain and Other Nervous System				
Male	2	4.0	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)
Breast				
Male	1	0.8	nc	(nc-nc)
Female	69	80.8	85.4	(66.4-108.0)
Cervix Uteri				
Female	3	2.5	nc	(nc-nc)
Colon / Rectum				
Male	22	24.0	91.6	(57.4-138.7)
Female	19	20.4	93.0	(56.0-145.2)
Esophagus				
Male	8	6.0	132.4	(57.0-260.8)
Female	1	1.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	8	12.4	64.7	(27.9-127.5)
Female	6	6.3	94.6	(34.6-206.0)
Larynx				
Male	3	3.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Leukemia				
Male	7	9.0	77.8	(31.2-160.2)
Female	4	5.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	5	7.7	64.6	(20.8-150.7)
Female	1	2.4	nc	(nc-nc)
Lung and Bronchus				
Male	36	42.6	84.4	(59.1-116.9)
Female	41	38.4	106.7	(76.6-144.8)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	14	14.3	97.9	(53.5-164.2)
Female	6	9.5	62.9	(23.0-136.9)
Multiple Myeloma				
Male	5	4.8	104.4	(33.6-243.7)
Female	4	3.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	16	12.8	124.8	(71.3-202.6)
Female	15	10.0	149.9	(83.8-247.3)
Oral Cavity & Pharynx				
Male	8	10.3	77.6	(33.4-153.0)
Female	4	4.3	nc	(nc-nc)
Ovary				
Female	5	6.9	72.5	(23.4-169.2)
Pancreas				
Male	13	8.3	157.0	(83.5-268.5)
Female	9	7.3	122.5	(55.9-232.5)
Prostate				
Male	74	73.9	100.1	(78.6-125.7)
Stomach				
Male	5	5.6	89.8	(28.9-209.5)
Female	3	2.7	nc	(nc-nc)
Testis				
Male	1	2.1	nc	(nc-nc)
Thyroid				
Male	6	5.0	119.0	(43.5-259.0)
Female	18	13.7	131.2	(77.7-207.4)
Uteri Corpus and Uterus, NOS				
Female	11	18.8	58.4	(29.1-104.5)
All Sites / Types				
Male	272	295.9	91.9	(81.3-103.5)
Female	250	267.7	93.4	(82.2-105.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	21	21.3	98.8	(61.1-151.0)
Female	7	7.0	99.4	(39.8-204.8)
Brain and Other Nervous System				
Male	1	3.5	nc	(nc-nc)
Female	5	2.8	177.3	(57.1-413.7)
Breast				
Male	2	0.7	nc	(nc-nc)
Female	98	70.5	139.0	(112.8-169.4)
Cervix Uteri				
Female	2	2.2	nc	(nc-nc)
Colon / Rectum				
Male	22	22.1	99.5	(62.3-150.7)
Female	22	20.8	105.6	(66.1-159.8)
Esophagus				
Male	0	5.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	4	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	11	10.5	105.2	(52.4-188.3)
Female	6	5.7	105.7	(38.6-230.0)
Larynx				
Male	3	2.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Leukemia				
Male	9	8.1	111.2	(50.7-211.1)
Female	10	5.5	181.1	(86.7-333.0)
Liver and Intrahepatic Bile Ducts				
Male	8	6.6	120.9	(52.1-238.2)
Female	4	2.2	nc	(nc-nc)
Lung and Bronchus				
Male	24	35.8	67.0	(42.9-99.7)
Female	32	34.8	91.8	(62.8-129.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	26	12.5	208.1	(135.9-305.0)
Female	20	8.7	230.3	(140.6-355.7)
Multiple Myeloma				
Male	7	4.1	171.9	(68.9-354.2)
Female	4	3.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	9	11.3	79.5	(36.3-150.9)
Female	6	9.5	63.5	(23.2-138.2)
Oral Cavity & Pharynx				
Male	7	8.9	78.9	(31.6-162.6)
Female	5	3.9	127.6	(41.1-297.9)
Ovary				
Female	10	6.1	163.2	(78.1-300.2)
Pancreas				
Male	9	7.3	122.9	(56.1-233.3)
Female	2	7.3	nc	(nc-nc)
Prostate				
Male	61	59.0	103.5	(79.1-132.9)
Stomach				
Male	1	4.9	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)
Testis				
Male	5	1.7	299.8	(96.6-699.6)
Thyroid				
Male	4	4.3	nc	(nc-nc)
Female	18	11.5	156.3	(92.6-247.1)
Uteri Corpus and Uterus, NOS				
Female	20	15.3	130.7	(79.8-201.9)
All Sites / Types				
Male	254	253.3	100.3	(88.3-113.4)
Female	296	244.4	121.1	(107.7-135.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	61	57.1	106.9	(81.8-137.3)
Female	42	24.0	175.1	(126.2-236.6)
Brain and Other Nervous System				
Male	11	11.3	97.1	(48.4-173.7)
Female	10	10.3	97.4	(46.6-179.2)
Breast				
Male	1	2.0	nc	(nc-nc)
Female	287	265.7	108.0	(95.9-121.3)
Cervix Uteri				
Female	4	8.7	nc	(nc-nc)
Colon / Rectum				
Male	69	62.6	110.3	(85.8-139.6)
Female	74	69.8	106.1	(83.3-133.2)
Esophagus				
Male	19	14.9	127.3	(76.6-198.8)
Female	5	4.7	106.8	(34.4-249.2)
Hodgkin Lymphoma				
Male	7	4.5	156.8	(62.8-323.1)
Female	2	3.8	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	38	32.7	116.2	(82.2-159.5)
Female	31	21.0	147.6	(100.2-209.5)
Larynx				
Male	14	8.8	159.7	(87.2-268.0)
Female	4	3.0	nc	(nc-nc)
Leukemia				
Male	19	23.5	81.0	(48.8-126.5)
Female	14	19.1	73.5	(40.1-123.3)
Liver and Intrahepatic Bile Ducts				
Male	22	20.4	107.6	(67.4-162.9)
Female	9	7.9	114.0	(52.0-216.5)
Lung and Bronchus				
Male	117	102.6	114.1	(94.3-136.7)
Female	163	126.2	129.2	(110.1-150.6)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	41	37.0	110.7	(79.4-150.1)
Female	47	32.6	144.1	(105.9-191.7)
Multiple Myeloma				
Male	10	11.9	83.9	(40.2-154.3)
Female	8	11.0	72.6	(31.3-143.1)
Non-Hodgkin Lymphoma				
Male	42	33.2	126.5	(91.1-171.0)
Female	30	33.6	89.2	(60.1-127.3)
Oral Cavity & Pharynx				
Male	29	27.9	104.0	(69.6-149.3)
Female	20	14.1	141.5	(86.4-218.5)
Ovary				
Female	22	22.8	96.4	(60.4-146.0)
Pancreas				
Male	17	20.6	82.6	(48.1-132.3)
Female	20	24.4	82.0	(50.1-126.7)
Prostate				
Male	172	181.6	94.7	(81.1-110.0)
Stomach				
Male	16	13.9	114.7	(65.5-186.3)
Female	7	9.4	74.1	(29.7-152.7)
Testis				
Male	9	8.2	110.2	(50.3-209.2)
Thyroid				
Male	14	15.0	93.1	(50.8-156.2)
Female	44	47.6	92.5	(67.2-124.2)
Uteri Corpus and Uterus, NOS				
Female	64	60.0	106.7	(82.2-136.3)
All Sites / Types				
Male	799	749.6	106.6	(99.3-114.2)
Female	971	891.5	108.9	(102.2-116.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	1.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	4	7.2	nc	(nc-nc)
Cervix Uteri				
Female	0	0.2	nc	(nc-nc)
Colon / Rectum				
Male	4	1.8	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)
Esophagus				
Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Larynx				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	1	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	1	3.0	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	2	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	1.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Ovary				
Female	0	0.6	nc	(nc-nc)
Pancreas				
Male	2	0.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Prostate				
Male	7	6.5	106.9	(42.8-220.2)
Stomach				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Testis				
Male	0	0.2	nc	(nc-nc)
Thyroid				
Male	0	0.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	4	1.7	nc	(nc-nc)
All Sites / Types				
Male	24	23.3	103.0	(66.0-153.3)
Female	13	23.6	55.0	(29.3-94.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	24	12.5	192.0	(123.0-285.6)
Female	8	4.5	176.7	(76.1-348.2)
Brain and Other Nervous System				
Male	2	2.9	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)
Breast				
Male	0	0.5	nc	(nc-nc)
Female	58	57.7	100.5	(76.3-129.9)
Cervix Uteri				
Female	5	2.1	240.3	(77.5-560.9)
Colon / Rectum				
Male	16	14.5	110.2	(62.9-178.9)
Female	14	13.6	102.6	(56.0-172.1)
Esophagus				
Male	6	3.5	169.7	(62.0-369.5)
Female	1	0.9	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	17	8.1	210.2	(122.4-336.5)
Female	4	4.4	nc	(nc-nc)
Larynx				
Male	3	2.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Leukemia				
Male	9	5.5	162.7	(74.3-308.9)
Female	3	4.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	2	4.9	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)
Lung and Bronchus				
Male	32	23.1	138.3	(94.6-195.3)
Female	43	24.6	174.6	(126.3-235.2)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	8	8.7	91.9	(39.5-181.0)
Female	14	7.1	195.9	(107.0-328.7)
Multiple Myeloma				
Male	0	2.8	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	2	7.8	nc	(nc-nc)
Female	5	6.8	73.7	(23.8-172.0)
Oral Cavity & Pharynx				
Male	7	7.0	100.3	(40.2-206.7)
Female	6	2.9	205.3	(75.0-446.8)
Ovary				
Female	3	4.9	nc	(nc-nc)
Pancreas				
Male	2	4.7	nc	(nc-nc)
Female	7	4.6	152.7	(61.2-314.7)
Prostate				
Male	45	45.0	100.0	(72.9-133.8)
Stomach				
Male	4	3.2	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)
Testis				
Male	1	2.3	nc	(nc-nc)
Thyroid				
Male	2	4.0	nc	(nc-nc)
Female	9	11.7	76.7	(35.0-145.6)
Uteri Corpus and Uterus, NOS				
Female	7	13.0	53.9	(21.6-111.1)
All Sites / Types				
Male	193	177.8	108.6	(93.8-125.0)
Female	205	186.5	109.9	(95.4-126.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	18	21.3	84.6	(50.1-133.7)
Female	10	7.0	142.2	(68.1-261.5)
Brain and Other Nervous System				
Male	3	3.5	nc	(nc-nc)
Female	7	2.8	247.5	(99.2-510.0)
Breast				
Male	0	0.7	nc	(nc-nc)
Female	80	74.0	108.1	(85.7-134.6)
Cervix Uteri				
Female	1	2.2	nc	(nc-nc)
Colon / Rectum				
Male	21	22.1	95.0	(58.8-145.3)
Female	15	20.7	72.4	(40.5-119.5)
Esophagus				
Male	2	5.3	nc	(nc-nc)
Female	4	1.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	10	11.0	91.2	(43.6-167.7)
Female	4	5.9	nc	(nc-nc)
Larynx				
Male	2	3.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Leukemia				
Male	3	8.1	nc	(nc-nc)
Female	7	5.5	128.0	(51.3-263.8)
Liver and Intrahepatic Bile Ducts				
Male	7	6.9	100.8	(40.4-207.7)
Female	2	2.2	nc	(nc-nc)
Lung and Bronchus				
Male	25	37.2	67.1	(43.4-99.1)
Female	24	35.7	67.2	(43.0-100.0)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	16	12.7	125.9	(71.9-204.5)
Female	9	8.9	101.1	(46.2-192.0)
Multiple Myeloma				
Male	4	4.2	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	9	11.5	78.4	(35.8-148.8)
Female	11	9.5	115.4	(57.5-206.5)
Oral Cavity & Pharynx				
Male	8	9.3	85.6	(36.9-168.7)
Female	2	4.0	nc	(nc-nc)
Ovary				
Female	8	6.4	125.1	(53.9-246.4)
Pancreas				
Male	3	7.5	nc	(nc-nc)
Female	10	7.3	136.4	(65.3-250.8)
Prostate				
Male	45	65.1	69.2	(50.4-92.5)
Stomach				
Male	5	5.0	100.2	(32.3-233.9)
Female	3	2.8	nc	(nc-nc)
Testis				
Male	1	1.8	nc	(nc-nc)
Thyroid				
Male	4	4.5	nc	(nc-nc)
Female	10	11.8	84.8	(40.6-156.0)
Uteri Corpus and Uterus, NOS				
Female	12	16.5	72.8	(37.5-127.1)
All Sites / Types				
Male	207	263.2	78.7	(68.3-90.1)
Female	241	250.8	96.1	(84.3-109.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	3.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	18	13.6	132.7	(78.6-209.8)
Cervix Uteri				
Female	0	0.4	nc	(nc-nc)
Colon / Rectum				
Male	3	3.6	nc	(nc-nc)
Female	4	3.5	nc	(nc-nc)
Esophagus				
Male	1	0.9	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	4	1.9	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)
Larynx				
Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	1	1.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Lung and Bronchus				
Male	5	6.1	82.4	(26.5-192.3)
Female	4	6.2	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	2.1	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	1.9	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	1.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Ovary				
Female	4	1.2	nc	(nc-nc)
Pancreas				
Male	1	1.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Prostate				
Male	6	11.6	51.6	(18.8-112.4)
Stomach				
Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Testis				
Male	0	0.4	nc	(nc-nc)
Thyroid				
Male	0	0.8	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	2	3.2	nc	(nc-nc)
All Sites / Types				
Male	30	44.2	67.8	(45.7-96.8)
Female	43	44.8	96.0	(69.5-129.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	10	10.6	94.7	(45.3-174.2)
Female	4	3.9	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	1.6	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)
Breast				
Male	0	0.3	nc	(nc-nc)
Female	25	33.8	74.0	(47.9-109.3)
Cervix Uteri				
Female	0	0.9	nc	(nc-nc)
Colon / Rectum				
Male	7	10.2	68.7	(27.5-141.6)
Female	8	11.1	71.9	(31.0-141.7)
Esophagus				
Male	3	2.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	4	4.6	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)
Larynx				
Male	0	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Leukemia				
Male	2	3.9	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	3.0	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)
Lung and Bronchus				
Male	5	17.4	28.7	(9.2-66.9)
Female	15	19.1	78.6	(44.0-129.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	4	5.8	nc	(nc-nc)
Female	3	4.4	nc	(nc-nc)
Multiple Myeloma				
Male	2	1.9	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	8	5.3	150.8	(64.9-297.1)
Female	4	5.1	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	3.9	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)
Ovary				
Female	4	3.1	nc	(nc-nc)
Pancreas				
Male	1	3.5	nc	(nc-nc)
Female	3	4.1	nc	(nc-nc)
Prostate				
Male	25	27.6	90.5	(58.5-133.5)
Stomach				
Male	2	2.3	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)
Testis				
Male	0	0.9	nc	(nc-nc)
Thyroid				
Male	2	1.8	nc	(nc-nc)
Female	5	5.3	93.9	(30.2-219.0)
Uteri Corpus and Uterus, NOS				
Female	4	7.7	nc	(nc-nc)
All Sites / Types				
Male	84	119.5	70.3	(56.1-87.1)
Female	94	126.1	74.6	(60.2-91.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	21	22.7	92.3	(57.1-141.1)
Female	9	8.4	107.6	(49.1-204.2)
Brain and Other Nervous System				
Male	4	4.7	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)
Breast				
Male	1	0.8	nc	(nc-nc)
Female	127	96.4	131.7	(109.8-156.7)
Cervix Uteri				
Female	3	3.3	nc	(nc-nc)
Colon / Rectum				
Male	22	25.5	86.2	(54.0-130.5)
Female	28	25.1	111.3	(74.0-160.9)
Esophagus				
Male	4	5.9	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)
Hodgkin Lymphoma				
Male	4	1.9	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	21	13.2	159.0	(98.4-243.1)
Female	7	7.5	92.9	(37.2-191.3)
Larynx				
Male	3	3.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)
Leukemia				
Male	14	9.6	145.1	(79.3-243.5)
Female	5	6.9	72.1	(23.2-168.1)
Liver and Intrahepatic Bile Ducts				
Male	6	8.1	74.4	(27.2-162.0)
Female	2	2.8	nc	(nc-nc)
Lung and Bronchus				
Male	46	39.7	115.9	(84.9-154.6)
Female	43	43.7	98.4	(71.2-132.6)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	12	14.8	81.0	(41.8-141.5)
Female	11	11.9	92.1	(45.9-164.9)
Multiple Myeloma				
Male	4	4.7	nc	(nc-nc)
Female	6	3.8	155.8	(56.9-339.2)
Non-Hodgkin Lymphoma				
Male	6	13.4	44.7	(16.3-97.3)
Female	16	11.9	134.2	(76.7-218.0)
Oral Cavity & Pharynx				
Male	13	11.4	114.1	(60.7-195.2)
Female	3	5.1	nc	(nc-nc)
Ovary				
Female	5	8.3	60.5	(19.5-141.2)
Pancreas				
Male	6	8.3	72.7	(26.5-158.2)
Female	6	8.5	70.2	(25.6-152.9)
Prostate				
Male	49	72.3	67.8	(50.2-89.6)
Stomach				
Male	4	5.6	nc	(nc-nc)
Female	5	3.4	146.3	(47.1-341.4)
Testis				
Male	2	3.3	nc	(nc-nc)
Thyroid				
Male	7	6.2	112.9	(45.2-232.6)
Female	13	18.1	72.0	(38.3-123.2)
Uteri Corpus and Uterus, NOS				
Female	21	21.2	99.0	(61.2-151.3)
All Sites / Types				
Male	270	299.9	90.0	(79.6-101.4)
Female	343	320.2	107.1	(96.1-119.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	11	11.7	93.7	(46.7-167.6)
Female	3	3.9	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	2.3	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)
Breast				
Male	0	0.4	nc	(nc-nc)
Female	35	47.4	73.8	(51.4-102.6)
Cervix Uteri				
Female	4	1.5	nc	(nc-nc)
Colon / Rectum				
Male	10	13.1	76.5	(36.6-140.8)
Female	16	11.6	138.3	(79.0-224.6)
Esophagus				
Male	2	3.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	8	6.8	118.1	(50.9-232.8)
Female	5	3.7	136.5	(44.0-318.6)
Larynx				
Male	2	1.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Leukemia				
Male	6	4.9	123.5	(45.1-268.7)
Female	1	3.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	4.3	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)
Lung and Bronchus				
Male	14	21.1	66.5	(36.3-111.6)
Female	19	21.5	88.2	(53.1-137.8)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	7.7	nc	(nc-nc)
Female	4	5.6	nc	(nc-nc)
Multiple Myeloma				
Male	3	2.4	nc	(nc-nc)
Female	4	1.8	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	4	6.8	nc	(nc-nc)
Female	4	5.7	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	7	5.9	119.0	(47.7-245.2)
Female	1	2.4	nc	(nc-nc)
Ovary				
Female	5	4.0	124.4	(40.1-290.4)
Pancreas				
Male	9	4.3	211.8	(96.6-402.0)
Female	5	3.9	127.3	(41.0-297.0)
Prostate				
Male	26	37.2	69.8	(45.6-102.3)
Stomach				
Male	2	2.9	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)
Testis				
Male	2	1.5	nc	(nc-nc)
Thyroid				
Male	2	3.1	nc	(nc-nc)
Female	7	8.5	82.4	(33.0-169.8)
Uteri Corpus and Uterus, NOS				
Female	9	10.6	84.9	(38.7-161.1)
All Sites / Types				
Male	120	154.6	77.6	(64.3-92.8)
Female	136	153.6	88.6	(74.3-104.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	22	23.6	93.4	(58.5-141.4)
Female	6	9.1	66.2	(24.2-144.1)
Brain and Other Nervous System				
Male	4	4.6	nc	(nc-nc)
Female	7	4.0	175.3	(70.2-361.2)
Breast				
Male	1	0.8	nc	(nc-nc)
Female	116	100.8	115.0	(95.1-138.0)
Cervix Uteri				
Female	2	3.3	nc	(nc-nc)
Colon / Rectum				
Male	28	25.7	108.9	(72.4-157.5)
Female	27	27.0	99.8	(65.8-145.3)
Esophagus				
Male	3	6.1	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	1.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	5	13.3	37.7	(12.1-87.9)
Female	12	7.9	151.8	(78.4-265.2)
Larynx				
Male	0	3.6	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)
Leukemia				
Male	15	9.6	156.5	(87.5-258.1)
Female	7	7.4	95.2	(38.1-196.1)
Liver and Intrahepatic Bile Ducts				
Male	6	8.1	73.8	(26.9-160.6)
Female	2	2.9	nc	(nc-nc)
Lung and Bronchus				
Male	22	42.3	52.0	(32.6-78.7)
Female	43	47.0	91.5	(66.2-123.2)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	16	15.0	106.5	(60.8-172.9)
Female	13	12.1	107.8	(57.3-184.3)
Multiple Myeloma				
Male	5	4.9	102.0	(32.9-238.1)
Female	3	4.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	17	13.5	125.6	(73.1-201.1)
Female	15	12.6	119.3	(66.7-196.8)
Oral Cavity & Pharynx				
Male	5	11.2	44.6	(14.4-104.1)
Female	5	5.3	94.1	(30.3-219.6)
Ovary				
Female	8	8.5	93.8	(40.4-184.8)
Pancreas				
Male	5	8.4	59.2	(19.1-138.1)
Female	10	9.4	106.6	(51.0-196.1)
Prostate				
Male	70	72.7	96.3	(75.1-121.7)
Stomach				
Male	4	5.7	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)
Testis				
Male	2	2.6	nc	(nc-nc)
Thyroid				
Male	5	5.9	84.4	(27.2-196.9)
Female	24	17.7	136.0	(87.1-202.3)
Uteri Corpus and Uterus, NOS				
Female	24	21.8	110.1	(70.5-163.9)
All Sites / Types				
Male	266	303.8	87.6	(77.4-98.8)
Female	353	336.4	104.9	(94.3-116.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	0	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Breast				
Male	0	0.0	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)
Cervix Uteri				
Female	0	0.1	nc	(nc-nc)
Colon / Rectum				
Male	5	1.5	334.4	(107.8-780.4)
Female	3	1.0	nc	(nc-nc)
Esophagus				
Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	0.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Larynx				
Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)
Leukemia				
Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Lung and Bronchus				
Male	1	2.4	nc	(nc-nc)
Female	4	1.8	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Ovary				
Female	1	0.4	nc	(nc-nc)
Pancreas				
Male	1	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Prostate				
Male	0	4.7	nc	(nc-nc)
Stomach				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Testis				
Male	0	0.1	nc	(nc-nc)
Thyroid				
Male	0	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	2	1.0	nc	(nc-nc)
All Sites / Types				
Male	11	18.0	61.2	(30.5-109.5)
Female	20	13.4	149.6	(91.3-231.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	21	22.1	95.1	(58.8-145.3)
Female	9	6.9	129.6	(59.1-246.0)
Brain and Other Nervous System				
Male	2	4.2	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)
Breast				
Male	1	0.8	nc	(nc-nc)
Female	83	81.5	101.9	(81.1-126.3)
Cervix Uteri				
Female	3	2.7	nc	(nc-nc)
Colon / Rectum				
Male	25	23.5	106.3	(68.8-157.0)
Female	28	20.2	138.9	(92.3-200.7)
Esophagus				
Male	7	5.9	118.4	(47.4-243.9)
Female	1	1.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.6	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	25	12.7	197.5	(127.7-291.5)
Female	12	6.4	187.2	(96.6-327.0)
Larynx				
Male	4	3.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Leukemia				
Male	5	8.8	56.7	(18.3-132.2)
Female	6	5.6	106.6	(38.9-232.1)
Liver and Intrahepatic Bile Ducts				
Male	9	8.0	112.3	(51.3-213.3)
Female	1	2.3	nc	(nc-nc)
Lung and Bronchus				
Male	53	40.9	129.7	(97.2-169.7)
Female	43	37.9	113.5	(82.2-152.9)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	28	14.2	197.6	(131.3-285.6)
Female	19	10.0	189.6	(114.1-296.0)
Multiple Myeloma				
Male	5	4.6	108.0	(34.8-252.1)
Female	6	3.2	186.2	(68.0-405.4)
Non-Hodgkin Lymphoma				
Male	6	12.6	47.6	(17.4-103.7)
Female	8	10.0	80.2	(34.5-158.0)
Oral Cavity & Pharynx				
Male	10	10.8	93.0	(44.5-171.0)
Female	2	4.2	nc	(nc-nc)
Ovary				
Female	6	7.0	86.1	(31.4-187.4)
Pancreas				
Male	15	8.0	188.0	(105.1-310.0)
Female	5	7.0	71.8	(23.1-167.5)
Prostate				
Male	69	74.5	92.6	(72.1-117.2)
Stomach				
Male	5	5.4	93.2	(30.0-217.6)
Female	3	2.7	nc	(nc-nc)
Testis				
Male	2	2.7	nc	(nc-nc)
Thyroid				
Male	7	5.5	127.1	(50.9-261.9)
Female	14	15.2	91.9	(50.2-154.2)
Uteri Corpus and Uterus, NOS				
Female	19	18.4	103.1	(62.1-161.1)
All Sites / Types				
Male	325	292.5	111.1	(99.4-123.9)
Female	292	268.7	108.7	(96.6-121.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	52	41.0	126.8	(94.7-166.3)
Female	21	16.3	129.0	(79.8-197.2)
Brain and Other Nervous System				
Male	5	8.1	61.6	(19.9-143.8)
Female	11	6.9	160.5	(80.0-287.2)
Breast				
Male	0	1.4	nc	(nc-nc)
Female	214	171.8	124.6	(108.5-142.4)
Cervix Uteri				
Female	8	5.8	138.6	(59.7-273.0)
Colon / Rectum				
Male	60	44.5	134.9	(102.9-173.6)
Female	53	48.0	110.4	(82.7-144.3)
Esophagus				
Male	12	10.4	115.9	(59.8-202.5)
Female	1	3.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	3	3.4	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	24	22.7	105.7	(67.7-157.3)
Female	16	13.8	115.9	(66.2-188.2)
Larynx				
Male	4	6.0	nc	(nc-nc)
Female	6	1.9	311.3	(113.7-677.6)
Leukemia				
Male	21	16.9	124.5	(77.0-190.3)
Female	11	13.1	83.7	(41.7-149.8)
Liver and Intrahepatic Bile Ducts				
Male	16	14.1	113.7	(65.0-184.7)
Female	3	5.2	nc	(nc-nc)
Lung and Bronchus				
Male	98	72.2	135.7	(110.2-165.4)
Female	82	83.0	98.7	(78.5-122.6)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	29	26.4	109.9	(73.6-157.9)
Female	17	22.0	77.3	(45.0-123.8)
Multiple Myeloma				
Male	10	8.2	121.2	(58.0-223.0)
Female	8	7.3	109.3	(47.0-215.3)
Non-Hodgkin Lymphoma				
Male	34	23.6	144.1	(99.8-201.4)
Female	30	22.5	133.2	(89.9-190.2)
Oral Cavity & Pharynx				
Male	17	19.3	88.2	(51.4-141.3)
Female	6	9.3	64.2	(23.5-139.8)
Ovary				
Female	15	15.0	100.0	(55.9-165.0)
Pancreas				
Male	12	14.6	82.0	(42.3-143.3)
Female	19	16.7	114.1	(68.6-178.1)
Prostate				
Male	120	124.7	96.2	(79.8-115.1)
Stomach				
Male	8	9.9	80.7	(34.7-158.9)
Female	6	6.6	91.4	(33.4-199.0)
Testis				
Male	6	6.5	91.7	(33.5-199.6)
Thyroid				
Male	14	10.7	130.6	(71.3-219.1)
Female	37	31.7	116.8	(82.2-161.0)
Uteri Corpus and Uterus, NOS				
Female	35	37.8	92.5	(64.4-128.7)
All Sites / Types				
Male	607	527.9	115.0	(106.0-124.5)
Female	664	590.1	112.5	(104.1-121.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	169	150.9	112.0	(95.8-130.2)
Female	60	62.0	96.8	(73.9-124.6)
Brain and Other Nervous System				
Male	32	33.0	97.0	(66.3-136.9)
Female	23	29.2	78.7	(49.9-118.2)
Breast				
Male	2	5.2	nc	(nc-nc)
Female	617	676.9	91.1	(84.1-98.6)
Cervix Uteri				
Female	30	24.2	124.2	(83.8-177.3)
Colon / Rectum				
Male	156	167.6	93.1	(79.0-108.9)
Female	177	185.0	95.7	(82.1-110.9)
Esophagus				
Male	53	38.9	136.3	(102.1-178.3)
Female	18	11.9	151.3	(89.6-239.1)
Hodgkin Lymphoma				
Male	14	15.1	92.9	(50.8-155.9)
Female	18	13.4	134.5	(79.6-212.5)
Kidney & Renal Pelvis				
Male	93	86.4	107.6	(86.9-131.8)
Female	64	54.3	117.9	(90.8-150.5)
Larynx				
Male	19	22.6	84.2	(50.7-131.6)
Female	12	7.5	159.8	(82.5-279.2)
Leukemia				
Male	74	65.5	113.0	(88.7-141.9)
Female	52	53.1	97.8	(73.1-128.3)
Liver and Intrahepatic Bile Ducts				
Male	82	53.9	152.2	(121.1-188.9)
Female	26	20.1	129.1	(84.3-189.2)
Lung and Bronchus				
Male	325	264.2	123.0	(110.0-137.2)
Female	350	318.6	109.8	(98.6-122.0)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	72	99.2	72.6	(56.8-91.4)
Female	61	88.7	68.7	(52.6-88.3)
Multiple Myeloma				
Male	24	31.0	77.4	(49.6-115.2)
Female	27	28.1	96.1	(63.3-139.8)
Non-Hodgkin Lymphoma				
Male	105	89.8	116.9	(95.6-141.5)
Female	72	87.4	82.4	(64.5-103.8)
Oral Cavity & Pharynx				
Male	72	74.0	97.3	(76.1-122.5)
Female	37	36.7	100.9	(71.0-139.1)
Ovary				
Female	47	59.4	79.1	(58.1-105.2)
Pancreas				
Male	52	54.3	95.8	(71.5-125.6)
Female	63	63.5	99.2	(76.2-126.9)
Prostate				
Male	476	470.6	101.2	(92.3-110.7)
Stomach				
Male	35	36.9	94.9	(66.1-132.0)
Female	22	25.1	87.6	(54.9-132.6)
Testis				
Male	23	29.0	79.3	(50.2-119.0)
Thyroid				
Male	44	42.6	103.4	(75.1-138.8)
Female	131	137.9	95.0	(79.4-112.7)
Uteri Corpus and Uterus, NOS				
Female	167	148.2	112.7	(96.2-131.1)
All Sites / Types				
Male	2080	1994.9	104.3	(99.8-108.8)
Female	2274	2324.2	97.8	(93.9-101.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	2	2.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Brain and Other Nervous System				
Male	2	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Breast				
Male	1	0.1	nc	(nc-nc)
Female	5	6.3	78.8	(25.4-183.8)
Cervix Uteri				
Female	0	0.2	nc	(nc-nc)
Colon / Rectum				
Male	2	2.0	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)
Esophagus				
Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	1.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Larynx				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	2	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	7	3.5	200.4	(80.3-413.0)
Female	0	2.8	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	1.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	3	1.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Ovary				
Female	0	0.6	nc	(nc-nc)
Pancreas				
Male	0	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Prostate				
Male	3	6.5	nc	(nc-nc)
Stomach				
Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	0	0.2	nc	(nc-nc)
Thyroid				
Male	0	0.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	5	1.6	318.7	(102.7-743.6)
All Sites / Types				
Male	26	25.0	103.8	(67.8-152.1)
Female	21	20.4	102.7	(63.6-157.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	10	9.7	103.5	(49.6-190.4)
Female	4	4.4	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	2.2	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)
Breast				
Male	0	0.4	nc	(nc-nc)
Female	64	51.4	124.5	(95.9-159.0)
Cervix Uteri				
Female	2	1.7	nc	(nc-nc)
Colon / Rectum				
Male	19	11.8	160.6	(96.6-250.8)
Female	12	13.6	88.2	(45.5-154.1)
Esophagus				
Male	5	2.7	186.8	(60.2-435.9)
Female	0	0.8	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	6	6.2	96.3	(35.2-209.5)
Female	4	4.0	nc	(nc-nc)
Larynx				
Male	1	1.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Leukemia				
Male	4	4.2	nc	(nc-nc)
Female	1	3.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	4	4.0	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)
Lung and Bronchus				
Male	19	17.4	109.0	(65.6-170.2)
Female	15	22.8	65.7	(36.7-108.3)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	9	6.8	132.7	(60.6-252.0)
Female	10	6.2	160.1	(76.6-294.4)
Multiple Myeloma				
Male	0	2.1	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	14	6.1	229.1	(125.2-384.5)
Female	5	6.3	78.9	(25.4-184.1)
Oral Cavity & Pharynx				
Male	3	5.5	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)
Ovary				
Female	6	4.4	136.6	(49.9-297.4)
Pancreas				
Male	5	3.7	135.4	(43.6-316.0)
Female	5	4.5	111.8	(36.0-260.9)
Prostate				
Male	56	33.0	169.8	(128.3-220.5)
Stomach				
Male	3	2.5	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)
Testis				
Male	2	1.5	nc	(nc-nc)
Thyroid				
Male	4	3.0	nc	(nc-nc)
Female	8	9.2	87.1	(37.5-171.6)
Uteri Corpus and Uterus, NOS				
Female	6	11.2	53.4	(19.5-116.2)
All Sites / Types				
Male	179	136.0	131.6	(113.0-152.3)
Female	165	169.3	97.4	(83.1-113.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	54	46.2	116.9	(87.8-152.6)
Female	21	17.2	122.1	(75.6-186.7)
Brain and Other Nervous System				
Male	8	6.4	125.8	(54.2-247.9)
Female	8	5.9	136.7	(58.9-269.4)
Breast				
Male	1	1.4	nc	(nc-nc)
Female	179	154.9	115.5	(99.2-133.8)
Cervix Uteri				
Female	1	4.2	nc	(nc-nc)
Colon / Rectum				
Male	40	44.2	90.5	(64.6-123.2)
Female	37	47.1	78.5	(55.3-108.2)
Esophagus				
Male	17	10.2	167.0	(97.3-267.5)
Female	6	3.3	184.1	(67.2-400.8)
Hodgkin Lymphoma				
Male	4	2.0	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	15	19.6	76.5	(42.8-126.2)
Female	12	13.2	91.2	(47.1-159.3)
Larynx				
Male	4	5.7	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)
Leukemia				
Male	35	16.3	214.5	(149.4-298.3)
Female	21	12.3	170.7	(105.6-260.9)
Liver and Intrahepatic Bile Ducts				
Male	19	12.6	150.2	(90.4-234.6)
Female	9	5.2	174.8	(79.7-331.8)
Lung and Bronchus				
Male	78	76.5	101.9	(80.5-127.2)
Female	99	88.6	111.8	(90.9-136.1)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	42	25.3	166.0	(119.6-224.4)
Female	43	18.6	230.8	(167.0-310.8)
Multiple Myeloma				
Male	7	8.4	83.6	(33.5-172.3)
Female	8	7.4	108.4	(46.7-213.6)
Non-Hodgkin Lymphoma				
Male	25	22.8	109.9	(71.1-162.2)
Female	24	21.8	109.9	(70.4-163.5)
Oral Cavity & Pharynx				
Male	19	16.1	118.1	(71.1-184.5)
Female	14	8.8	159.6	(87.2-267.7)
Ovary				
Female	9	13.6	66.4	(30.3-126.0)
Pancreas				
Male	18	15.1	119.4	(70.7-188.8)
Female	19	17.3	109.5	(65.9-171.1)
Prostate				
Male	140	110.7	126.4	(106.4-149.2)
Stomach				
Male	6	10.3	58.4	(21.3-127.0)
Female	7	6.4	108.5	(43.5-223.6)
Testis				
Male	2	2.9	nc	(nc-nc)
Thyroid				
Male	9	7.3	123.0	(56.1-233.4)
Female	11	21.7	50.7	(25.3-90.7)
Uteri Corpus and Uterus, NOS				
Female	29	34.2	84.7	(56.7-121.7)
All Sites / Types				
Male	581	505.6	114.9	(105.8-124.6)
Female	611	553.9	110.3	(101.7-119.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;